The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict MedAssets's revenues will increase 9.9% and EPS will grow 25.0%.
The average estimate for revenue is $164.7 million. On the bottom line, the average EPS estimate is $0.30.
Last quarter, MedAssets booked revenue of $163.8 million. GAAP reported sales were 4.5% higher than the prior-year quarter's $156.8 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.27. GAAP EPS were -$0.25 for Q4 versus $0.07 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 76.8%, 330 basis points worse than the prior-year quarter. Operating margin was 15.6%, 40 basis points better than the prior-year quarter. Net margin was -8.8%, much worse than the prior-year quarter.
The full year's average estimate for revenue is $680.2 million. The average EPS estimate is $1.29.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 61 members out of 73 rating the stock outperform, and 12 members rating it underperform. Among 28 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 23 give MedAssets a green thumbs-up, and five give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on MedAssets is outperform, with an average price target of $19.82.
Is MedAssets the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add MedAssets to My Watchlist.